Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 3299 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
 

Table of Contents   
ORIGINAL ARTICLE  
Year : 2016  |  Volume : 27  |  Issue : 6  |  Page : 1114-1122
Serum levels of N-terminal-pro B-type natriuretic peptide as a diagnostic marker for left ventricular dysfunction in children with end-stage renal disease on hemodialysis


1 Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt
2 Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt

Click here for correspondence address and email

Date of Web Publication28-Nov-2016
 

   Abstract 

The objective of this study was to determine the diagnostic cutoff value of N-terminal-pro B-type natriuretic peptide (NT-pro BNP) as a marker of left ventricular (LV) dysfunction in children with end-stage renal disease (ESRD) on regular hemodialysis (HD). The study was carried out on thirty children with ESRD on regular HD and thirty healthy controls. Echocardiographic studies were done, including a conventional mode for ejection fraction, fractional shortening, tissue Doppler imaging, and longitudinal global strain by speckle tracking. Serum levels of NT-pro BNP were measured in venous blood samples before and about 30 min after HD by ELISA. Volume status was assessed by calculating interdialytic weight gain %. There were significant higher serum NT-pro BNP levels before HD (mean: 702.3 ± 274.3 ng/L) compared to controls (mean: 365.55 ± 76.5 ng/L) (P <0.001) and these levels decreased significantly after the HD session (mean: 625.1 ± 117.69 ng/L) (P = 0.031). Echocardiographic studies showed a significant impairment of LV function of the patients compared to controls. Patients with LV dysfunction had significant higher serum concentrations of NT-pro BNP compared to patients without dysfunction both before (P = 0.003) and after dialysis (P <0.001). Receiver operating curve demonstrated better prediction of LV dysfunction by NT-pro BNP levels after HD compared to its levels before HD (area under the curve was 0.9 and 0.73, respectively). Using a cutoff value of 630 ng/L, serum NT-pro BNP levels after dialysis were a diagnostic predictor of LV dysfunction with a sensitivity of 86.6%, specificity of 93.3%, positive predictive value of 92.8%, and negative predictive value of 87.5%. Serum NT-pro BNP levels were strongly correlated with the parameters of LV dysfunction in children with ESRD on regular HD. A postdialysis cutoff value of 630 ng/L could serve as a biochemical marker of LV dysfunction in those children regardless of chronic fluid overload.

How to cite this article:
Zoair AM, Abdel-Hafez MA, Mawlana W, Sweylam MA. Serum levels of N-terminal-pro B-type natriuretic peptide as a diagnostic marker for left ventricular dysfunction in children with end-stage renal disease on hemodialysis. Saudi J Kidney Dis Transpl 2016;27:1114-22

How to cite this URL:
Zoair AM, Abdel-Hafez MA, Mawlana W, Sweylam MA. Serum levels of N-terminal-pro B-type natriuretic peptide as a diagnostic marker for left ventricular dysfunction in children with end-stage renal disease on hemodialysis. Saudi J Kidney Dis Transpl [serial online] 2016 [cited 2020 Jan 19];27:1114-22. Available from: http://www.sjkdt.org/text.asp?2016/27/6/1114/194593

   Introduction Top


End-stage renal disease (ESRD) is the stage of chronic renal failure, in which life is impossible without renal replacement therapy. It is associated with a high risk of cardiovascular disease, which remains the leading cause of death in dialysis patients. [1] New echocardiographic modalities such as tissue Doppler imaging (TDI) and speckle tracking echocardiography (STE) can detect subclinical cardiac dysfunction earlier with the advantages of being less load dependent. [2]

B-type natriuretic peptide (BNP) is synthesized as prepro-BNP mainly in the ventricular myocardium. On ventricular myocyte stretch, prepro-BNP is enzymatically cleaved to pro BNP and released in the form of the hormonally active BNP and the inactive N-terminalpro BNP (NT-pro BNP). [3]

BNP is metabolized by natriuretic peptide receptors, which are mainly located in the liver, lung, kidney, and vascular endothelium, and degraded by plasma endopeptidases. [4] The amino terminal of pro BNP (NT-pro BNP) is predominantly cleared by the kidneys, and has a longer half-life than BNP (1-2 h vs. 20 min) leading to higher circulating levels and greater stability. NT-pro BNP levels show stronger correlation with an estimated glomerular filtration rate (eGFR) than the BNP. [5]

Measurements of both BNP and NT-pro BNP have an established role in screening of heart disease, diagnosis and stratification of patients with heart failure, detection of left ventricular (LV) systolic and/or diastolic dysfunction, and differential diagnosis of acute dyspnea. [6] A cutoff value of plasma NT-pro BNP for the diagnosis of heart failure in children without kidney diseases was studied and stratified according to the age groups. [7] However, in children with ESRD, their use is confounded by reduced renal excretion and concomitant chronic volume overload, and the cutoff values are expected to be different. The aim of this work was to evaluate the diagnostic value of NT-pro BNP as a marker of LV dysfunction in children with ESRD on regular hemodialysis (HD) and to correlate its levels with echocardiographic LV parameters of those children.


   Patients and Methods Top


The present study was carried out at Pediatric Department, Tanta University Hospitals. The study was conducted as a prospective case- control analysis of thirty children with ESRD on regular HD. Their ages ranged from 5-16 years. Thirty ageand sex-matched healthy children were included as a control group. The study started from October 2013 to December 2014 with the approval of the Ethical Committee and Institutional Review Board at the Faculty of Medicine, Tanta University, Egypt. All the parents of the included children signed a written informed consent before enrollment into the study.

All patients were on regular HD three times per week, each dialysis session lasting for 3-4 h. Dialysis was started when the glomerular filtration rate was ≤15 mL/min/1.73 m 2 . Exclusion criteria were children with congenital cardiac anomalies, chromosomal anomalies, current infections, uncontrolled hypertension, severe anemia, and clinically evident heart failure.

Patients were dialyzed on Fresenius 4008-B dialysis machine (Germany) at a blood flow rate = 2.5 × weight (kg) + 100 mL/min, using polysulfone hollow fiber dialyzers suitable for the surface area of the patients (Fresenius F3 = 0.4 m 2 , F4 = 0.7 m 2 , F5 = 1.0 m 2 , and F6 = 1.2 m 2 ). Bicarbonate dialysis solutions were used (Na: 138 mEq/L, K: 2 mEq/L, Ca: 5 mg/dL, and bicarbonate: 32 mEq/L). The dialysate temperature was 36.5°C.

All patients and controls were subjected to detailed history taking, including duration of dialysis and regular drug taking, clinical examination including blood pressure and cardiac examination. Clinical and radiological measurements were taken on the dialysis-free day.

Arterial blood pressure was measured by the auscultatory method using a mercury sphygmomanometer with the patient in the semisitting position after 10 min of rest, in the non fistula arm using an appropriate-sized cuff. All measurements were performed twice and the means were used for analysis.

Interdialytic weight gain (IDWG) was calculated as percent from dry weight as follows:

Predialysis weight − Postdialysis weight (dry weight) × 100/postdialysis weight

Kt/V was used for the evaluation of dialysis adequacy.

Routine laboratory investigations were complete urine analysis, complete blood picture (complete blood cell), blood urea and serum creatinine, serum albumin, total serum cholesterol levels, serum electrolytes, serum Ca, phosphorous, C-reactive protein, and intact parathyroid hormone. These investigations were done as part of the routine laboratory work.

Echocardiographic studies were done using a commercially available ultrasound transducer and equipment (Vivid 7; GE Healthcare, Horten, Norway). Data acquisition was performed with a 3.5-MHz transducer. To avoid intraobserver variability, two examinations were done by the same operator who was blind for the volume status and the levels of NT-pro BNP.

Conventional echocardiography was conducted using M-mode and two-dimensional (2D) images to assess LV internal dimensions, ejection fraction (EF), and fractional shortening (FS). All children were examined in a semisupine, left lateral position. The LV diastolic functions were evaluated by the mitral inflow pattern obtained by pulsed-wave Doppler echocardiography. The mitral Doppler signals were recorded in the apical 4-chamber view, with the Doppler sample volume placed at the tip of the mitral valve. [8]

Pulsed wave TDI (PW-TDI) was performed using pulsed-wave angle-corrected color-coded TDI filters. The baseline was adjusted to a low-velocity range (-20 to 20 cm/s), and Doppler frame rates were varied between 80 and 115 frames/s depending on the sector width of the range of interest with minimal gain setting to minimize background noise and to obtain the highest quality images. The sample volume was placed within the myocardium equidistant from the endocardial and epicardial borders. From the apical 4-chamber planes, using PW-TDI, the myocardial velocity curves of the septal mitral valve annulus and lateral mitral valve annulus were recorded. The electrocardiogram was connected and traced simultaneously to define the timing of cardiac cycle events. The beginning of QRS complex was used as a reference point. The spectral TDI display showed an antegrade systolic (S) wave and two retrograde waves, E′ (passive LV filling), and A′ wave (atrial contraction). The S wave reflects the LV systolic function, and the E΄/A΄ ratio of the mitral valve annulus reflects the diastolic dysfunction of the LV.

For speckle tracking analysis of the left ventricle, standard gray scale 2D images were acquired in the 4-chamber view using a 3.5 MHz transducer at a depth of 16 cm with a stable electrocardiograph recording using acoustic tracking software (EchoPAC; allowing offline semi-automated analysis of speckle-based strain) to measure global systolic LV with the frame rates of 60-1000 frames/s. Particular attention was given to obtain a satisfactory gray scale image, allowing reliable delineation of myocardial tissue and extracardiac structures. Three consecutive heart cycles were recorded and averaged. To avoid intra-observer variability, two examinations were performed by the same operator.

LV systolic strain: for apical long-axis, 2and 4-chamber views, three sampling points were placed manually at septal mitral annulus, lateral corner, and apical endocardium. A region of interest (ROI) was then generated by the software to cover the myocardial thickness along the entire LV wall. The ROI was adjusted manually to ensure that the inner margin confirmed to the whole LV endocardial border and that it included the entire thickness of the LV myocardium. The software subsequently identified the tissue speckles and tracked their movement frame-by-frame throughout the cardiac cycle. The automated function imaging was used to measure segmental peak systolic strain in LV walls and global peak longitudinal systolic strain in the three standard apical views. The average LV global longitudinal systolic strain (LV GLSS) was calculated from the three individual apical GLSS curves. As the longitudinal strain analysis was performed in all the three apical views, the software automatically generated a topographic representation of all the 17 analyzed segments. The average LV GLSS was calculated by averaging the peak systolic values of the 17 segments, derived from the 6 segments of the 3 apical views. For myocardial strain, regional lengthening is expressed as a positive value (or blue) and shortening as a negative value (or red).

Patient group was further divided into ventricular dysfunction and nondysfunction groups. LV dysfunction was considered in this study if the patient has any of the following: EF <45%, FS <25%, E/E΄ >15, or global strain <15%. [9]

Blood samples were drawn from the vascular access just before and about 30 min after HDs for the measurement of NT-proBNP. After centrifugation, samples were stored at -70°C till the time of analysis. Serum NT-pro-BNP was analyzed using a commercial NT-proBNP ELISA kit (Biomedica, Vienna, Austria).


   Statistical Analysis Top


Data were analyzed using Statistical Package for the Social Science (SPSS) software version 16, (SPSS Inc., Chicago, IL, USA). Data were expressed as the number and percentage for nonparametric variables and mean ± standard deviation for parametric variables. For comparison of means of two independent groups, unpaired Student's t-test was used. Paired Student's t-test was used to compare means of the same group (before and after dialysis). Pearson's bivariate correlation coefficient was used for analyzing the correlation between variables.

Receiver operating curve (ROC) characteristic was used to determine cutoff value of NT-pro BNP in diagnosing LV dysfunction. The upper left corner location of the curve indicates a good sensitivity and specificity of plasma NT-pro BNP level in diagnosing ventricular dysfunction. The area under the curve represents the overall accuracy of the NT-pro BNP measurements.


   Results Top


The demographic, clinical, and laboratory data of the studied groups are shown in [Table 1]. There was no statistically significant difference between both groups regarding age (P >0.05). Female sex represented 60% of our patients and 56.6% of the control group. There was a statistically significant increase in heart rate, systolic and diastolic blood pressure in patients compared to the controls (P <0.05).
Table 1: Demographic, clinical, and laboratory data of the studied groups.

Click here to view


Chronic glomerulonephritis represents the most common cause of ESRD (50%) followed by chronic pyelonephritis (16.6%). Obstructive uropathy and hypoplastic kidneys represent 13.3% for each and hereditary nephropathy represent 6.6%.

The duration of HD before the study ranged from twelve to 65 months with a median of 41.3 months. Serum albumin and Hb% were significantly lower while total serum cholesterol, blood urea, and CRP were significantly higher in patients compared to controls [Table 1]. Patients' mean weight before dialysis was 29.6 ± 5.34 kg and after HD it was 28.65 ± 5.4 with mean IDWG% of 3.5 ± 1.72.

Echocardiographic study showed significant impairment of the cardiac functions of patients by conventional echo, tissue Doppler, and global strain by speckle tracking compared to healthy controls [Table 2]. Systolic dysfunction was evident by decreased EF (P <0.05) and FS (P <0.05) in conventional echocardiography and decreased S wave (P <0.001) by tissue Doppler study while diastolic dysfunction was evident by the high E/E΄ ratio (P <0.001). Longitudinal global strain of the LV was significantly lower in patients compared to controls (P <0.001) which denote both systolic and diastolic dysfunctions. Fifteen (50%) patients had LV dysfunction either systolic or diastolic or both. Most of the patients with LV dysfunction were diagnosed by tissue Doppler or speckle tracking. Conventional echo parameters (EF and FS) were lower but not significantly different in patients with and without LV dysfunction [Table 3].
Table 2: Echocardiographic data of the studied groups.

Click here to view
Table 3: Clinical, laboratory, and echocardiographic data in patients with and without LV failure.

Click here to view


There were statistically significant higher serum levels of NT-pro BNP in the patient group before HD compared to its levels after HD (P = 0.031). There were also statistically significant higher serum NT-pro BNP levels in the patient group as compared to the control group (P <0.001) [Table 4]. Serum levels of NT-pro BNP in patients with LV dysfunction were highly elevated compared to patients without LV dysfunction both before (P = 0.003) and after (P <0.001) HD [Table 3]. No statistically significant differences were found between patients with and without LV dysfunction as regard Hb%, serum albumin, total cholesterol, or blood pressure (P >0.05). IDWG was statistically significantly higher in patients with LV dysfunction (P <0.001, [Table 3].
Table 4: Serum levels of NT-pro BNP of the studied groups.

Click here to view


ROC curve demonstrated better prediction of LV dysfunction by NT-pro BNP levels after HD compared to its levels before HD (area under the curve was 0.9 and 0.73, respectively) Using a cutoff value of 630 ng/L, serum NTpro BNP levels after dialysis were a diagnostic predictor of LV dysfunction with a sensitivity of 86.6%, specificity of 93.3%, positive predictive value of 92.8%, and negative predictive value of 87.5% [Figure 1] and [Table 5]. There was nonsignificant correlation between plasma NT-pro BNP levels and age, duration of dialysis, systolic and diastolic blood pressure, and IDWG%. There was a significant negative correlation between serum levels of NT-pro BNP and FS% and EF%, S wave, and global longitudinal strain, and significant positive correlation with LV E/E΄ ratio.
Figure 1: Receiver operating curve curves of serum N-terminal-pro B-type natriuretic peptide concentrations before and after hemodialysis and presence of left ventricular dysfunction. The upper left corner location of the curves indicates a good sensitivity and specificity of the N-terminal pro B-type natriuretic peptide in diagnosing left ventricular dysfunction. The area under the curve represents the overall accuracy of the N-terminal-pro B-type natriuretic peptide measurement.

Click here to view
Table 5: Validity of NT-pro BNP in prediction of diagnosis.

Click here to view



   Discussion Top


Serum levels of NT-pro-BNP were highly elevated in children with ESRD undergoing regular HD. Patients with and without LV dysfunction, as evidenced by echocardiographic assessments, had higher concentrations compared to controls. This may explain the difficulty of using this marker for the diagnosis of heart failure in those patients.

Many studies reported higher levels of natriuretic peptides in ESRD patients as a result of chronic volume overload and decreased renal excretion. [10],[11],[12],[13],[14],[15],[16],[17] In HD patients, fluid overload is multifactorial, including, inadequate dialysis, excessive water intake, absent residual renal function and patient noncompliance with treatment regulations. This fluid imbalance may contribute to the elevated levels of plasma NT-pro BNP without evidence of cardiac dysfunction.

The effect of dialysis on serum concentration of NT-pro-BNP is controversial. Some studies demonstrated a significant reduction similar to this study [11],[14] while others found either no changes or increasing concentrations after dialysis. [12],[17] Madsen et al, had reported a decrease in NT-pro BNP by 39% using dialysis with high-flux membranes [11] and Bargnoux et al reported 59% reduction in its concentration by hemodiafiltration. [15] High-flux membranes have a higher ultra-filtration rate than low-flux membranes. The larger size of NT-pro BNP molecule (8.5 kDa) may be the factor responsible for low clearance by a low-flux membrane with narrow pores. We used low-flux membrane dialyzers in HD of our patients, and the significant reduction of NT-pro BNP concentrations may be explained by multiple factors. First, the elimination due to adhesion and adsorption over the membrane, second the restoration of normovolemia may decrease the synthesis of NT-pro BNP. However, the relatively long half-life (120 min) of NT-pro BNP will need more time for this effect to evolve. In the present study, postdialysis sampling was taken 30 min after the end of HD session; in most other studies, postdialysis sampling was taken immediately at the end of the session. Third, the efficacy of dialysis may be also a contributing factor, as levels of NT-pro BNP were dependent on the effectiveness of dialysis as assessed by Kt/V and this was also reported in a previous study. [12]

In the present study, we could demonstrate that postdialysis NT-pro BNP cutoff value more than 630 ng/L could be used for diagnosis of LV dysfunction in HD children, regardless of the children's fluid load with 93.3% sensitivity and 80% specificity. Area under ROC curve for postdialysis values were better than predialysis values, this may be explained by less effect of fluid overload in postdialysis values. The level of NT-pro BNP had been found to be a strong prognostic marker in a variety of disease states such as hypertension and heart diseases. [18],[19] In patients with ESRD on regular HD, the concentration of NT-pro BNP revealed increasing mortality with concomitant increasing concentrations, which was evident for both preand post-dialysis values. [11] This may explain the importance of determination of NT-pro BNP cutoff value for the use in clinical practice. Regular cardiac assessment and adequate control of volume status in HD patients will be of outmost importance to keep the levels of NT-pro BNP below the cutoff values to improve prognosis. However, before suggesting cutoff values to be used in clinical practice, larger cohorts will be needed in different age groups of the pediatric populations.

The present study showed that the patients with higher serum concentrations of NT-pro BNP before and after HD were diagnosed by echocardiography to have LV dysfunction. This was in agreement with Goto et al, and Naganuma et al, who reported that the preand post-dialysis plasma BNP values in patients with LV dysfunction were higher than that in normal LV function. [14],[17] Despite the lower values of EF and FS in patients compared to controls, their levels were not significantly different in patients diagnosed with and without LV dysfunction. Conventional echocardiography has its limitation in the detection of the LV dysfunction. Diastolic dysfunction, which is a common mechanism of heart failure in dialysis patients, is not adequately evaluated in conventional echocardiography parameter. TDI has gained an increasing acceptance as a mean of noninvasively assessing myocardial properties and has been demonstrated as a prognostic tool in cardiac diseases. 2D STE has emerged as a novel technique for objective and quantitative evaluation of global and regional myocardial function, independent of the angle of myocardial insonation. [20] LV dysfunction in the present study was detected in most of the patients by tissue Doppler and speckle tracking.

Fluid status in this study was assessed by calculating IDWG%. Achievement of dry weight is one target of HD. Dry weight is defined as the lowest body weight a patient can tolerate without developing intraor interdialytic hypotension or other symptoms of dehydration. [21] In most dialysis units, dry weight is determined depending on clinical basis. No correlation was found in this study between INWG% and NT-pro BNP levels, even postdialysis values. This may decrease the possibility of using NT-pro BNP as a more accurate marker for estimating dry weight in HD. In previous studies, the correlation between NT-pro BNP levels and acute changes in preload during dialysis was not found. [11],[13] This may explain the complexity of the factors controlling its levels and the need to adjust these factors.


   Limitations of the study Top


Assessment of fluid status is only clinical. Bioimpedance and ambulatory BP monitoring are not available in our center. The relatively few number of patients included in the study did not allow classifications and analysis of data according to those with combined systolic and diastolic failure and those with each type of failure alone. Cutoff values of NT-pro BNP that can be used in clinical practice need larger cohorts of different age groups in pediatric populations to be validated.


   Conclusion Top


Serum NT-pro BNP levels strongly correlated with LV echocardiographic parameters in patients with ESRD. Despite the high concentrations of NT-pro BNP in all dialysis children, its levels can be used as a diagnostic marker of LV dysfunction by using higher cutoff values. A postdialysis cutoff value of 630 ng/L could serve as a biochemical marker of early LV dysfunction regardless of chronic fluid overload. Long-term follow-up is required to evaluate the prognostic value of NT-pro BNP in those children.

Conflicts of interest: None declared.

 
   References Top

1.
Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050-65.  Back to cited text no. 1
    
2.
Abid L, Rekik H, Jarraya F, Kharrat I, Hachicha J, Kammoun S. Acute hemodialysis effects on doppler echocardiographic indices. Saudi J Kidney Dis Transpl 2014;25:756-61.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.
Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004;6:257-60.  Back to cited text no. 3
    
4.
Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000;167:239-46.  Back to cited text no. 4
    
5.
Alehagen U, Lindstedt G, Eriksson H, Dahlström U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 2003;49:1337-46.  Back to cited text no. 5
    
6.
Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006;175:611-7.  Back to cited text no. 6
    
7.
Lin CW, Zeng XL, Zhang JF, Meng XH. Determining the optimal cutoff values of plasma N-terminal pro-B-type natriuretic peptide levels for the diagnosis of heart failure in children of age up to 14 years. J Card Fail 2014;20:168-73.  Back to cited text no. 7
    
8.
Picard MH, Adams D, Bierig SM, et al. American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr 2011;24:1-10.  Back to cited text no. 8
    
9.
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388442.  Back to cited text no. 9
    
10.
Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and Nterminal proBNP by hemodialysis. Clin Chem 2004;50:1071-4.  Back to cited text no. 10
    
11.
Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007;71:548-54.  Back to cited text no. 11
    
12.
Lee SW, Song JH, Kim GA, Lim HJ, Kim MJ. Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis 2003;41: 1257-66.  Back to cited text no. 12
    
13.
Clerico A, Caprioli R, Del Ry S, Giannessi D. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001;24:24-30.  Back to cited text no. 13
    
14.
Goto T, Takase H, Toriyama T, et al. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 2002;92:610-5.  Back to cited text no. 14
    
15.
Bargnoux AS, Klouche K, Fareh J, et al. Prohormone brain natriuretic peptide (proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Correlation with ventricular function, fluid removal and effect of hemodiafiltration. Clin Chem Lab Med 2008;46:1019-24.  Back to cited text no. 15
    
16.
Jafri L, Kashif W, Tai J, et al. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function. BMC Nephrol 2013; 14:117.  Back to cited text no. 16
    
17.
Naganuma T, Sugimura K, Wada S, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002; 22:437-44.  Back to cited text no. 17
    
18.
Olsen MH, Wachtell K, Tuxen C, et al. Nterminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22:1597-604.  Back to cited text no. 18
    
19.
Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74.  Back to cited text no. 19
    
20.
Blessberger H, Binder T. NON-invasive imaging: Two dimensional speckle tracking echocardiography: basic principles. Heart 2010;96:716-22.  Back to cited text no. 20
    
21.
Onofriescu M, Mardare NG, Segall L, et al. Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int Urol Nephrol 2012;44:583-91.  Back to cited text no. 21
    

Top
Correspondence Address:
Maher Ahmed Abdel-Hafez
Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta
Egypt
Login to access the Email id


DOI: 10.4103/1319-2442.194593

PMID: 27900955

Rights and Permissions


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]



 

Top
   
 
 
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  
 


 
    Abstract
   Introduction
   Patients and Methods
   Statistical Analysis
   Results
   Discussion
    Limitations of t...
   Conclusion
    References
    Article Figures
    Article Tables
 

 Article Access Statistics
    Viewed1521    
    Printed12    
    Emailed0    
    PDF Downloaded261    
    Comments [Add]    

Recommend this journal